STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012
March 1, 2023 updated by: Global Alliance to Immunize Against AIDS Vaccine Foundation
Knowledge, Attitudes, Practices and Willingness to Vaccinate in Preparation for the Introduction of HPV Vaccines in Bamako, Mali
Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions.
In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings.
To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations.
In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali.
The survey was combined with a brief educational session on HPV.
Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI).
Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening.
After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination.
This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
301
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants were recruited between May and June 2011 in Mèkin-Sikoro and Djikoroni, two peri-urban communities of Bamako that have been site for previous population surveys.
Adolescents were eligible if aged 12-17 years and living in the household, and if a guardian was available to provide consent.
Adults (male and female) were eligible if aged >18 years and living in the household.
A total of 301 participants participated (150 living in households in Djikoroni, 151 living in Me´kin-Sikoro)
Description
Inclusion Criteria:
- 12-17 years of age, with guardian consent
- 18 years or older
- Male or Female
- Living in Mèkin-Sikoro and Djikoroni
Exclusion Criteria:
- 12-17 years of age, without guardian consent
- <12 years of age
- Living outside Mèkin-Sikoro and Djikoroni
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Bamako Participants
301 male and female participants.
Teenagers and adults.
Living in two urban regions of Bamako.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants' acceptance of the vaccine
Time Frame: immediately after the intervention
|
Number of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions
|
immediately after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knowledge of STIs, HPV, and Cervical Cancer
Time Frame: immediately after the intervention
|
Knowledge Question asked before and after educational session
|
immediately after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Anne De Groot, MD, GAIA Vaccine Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
October 26, 2022
First Submitted That Met QC Criteria
March 1, 2023
First Posted (Actual)
March 14, 2023
Study Record Updates
Last Update Posted (Actual)
March 14, 2023
Last Update Submitted That Met QC Criteria
March 1, 2023
Last Verified
March 1, 2023
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.